{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:56Z","timestamp":1791912476409,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40265-020-01370-4","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T05:03:51Z","timestamp":1595999031000},"page":"1259-1264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Inebilizumab: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"issue":"4","key":"1370_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","volume":"92","author":"BG Weinshenker","year":"2017","unstructured":"Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92(4):663\u201379.","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"1370_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology."},{"key":"1370_CR3","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","volume":"2018","author":"MA Mealy","year":"2018","unstructured":"Mealy MA, Kessler RA, Rimler Z, et al. Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm. 2018;2018:e468.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1370_CR4","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","volume":"2","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, O\u2019Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e104.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"1370_CR5","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088\u201394.","journal-title":"J Neurol."},{"key":"1370_CR6","unstructured":"Viela Bio. Viela Bio reports fourth quarter and full year 2019 financial results and business highlights [media release] 25 Mar 2020. https:\/\/vielabio.com."},{"key":"1370_CR7","unstructured":"US Food & Drug Administration. FDA approves new therapy for rare disease affecting optic nerve, spinal cord [media release] 11 June 2020. https:\/\/www.fda.gov."},{"key":"1370_CR8","unstructured":"Viela Bio. UpliznaTM (inebilizumab-cdon): US prescribing information. 2020. https:\/\/www.accessdata.fda.gov. Accessed 1 July 2020."},{"key":"1370_CR9","unstructured":"MedImmune Inc. MedImmune completes cellective acquisition [media release] 17 Oct 2005. http:\/\/www.medimmune.com."},{"key":"1370_CR10","unstructured":"AstraZeneca. AstraZeneca successfully completes acquisition of MedImmune [media release] 19 June 2007. http:\/\/www.astrazeneca.com."},{"key":"1370_CR11","unstructured":"Astra Zeneca. MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics [media release] 28 Feb 2018. https:\/\/www.astrazeneca.com."},{"key":"1370_CR12","unstructured":"Viela Bio. Viela Bio spins out of MedImmune; launches with up to $250 Million Series A financing from investor consortium led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital [media release] 28 Feb 2018. http:\/\/www.vielabio.com."},{"key":"1370_CR13","unstructured":"Viela Bio. Viela Bio enters strategic collaboration with Hansoh Pharma to develop and commercialize inebilizumab for autoimmune diseases and hematologic cancers in China [media release] 28 May 2019. http:\/\/www.vielabio.com."},{"key":"1370_CR14","unstructured":"Mitsubishi Tanabe Pharma Corporation. Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions [media release] 9 Oct 2020. http:\/\/www.mt-pharma.co.jp."},{"issue":"12","key":"1370_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/jcm5120107","volume":"5","author":"D Chen","year":"2016","unstructured":"Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5(12):107.","journal-title":"J Clin Med."},{"issue":"1","key":"1370_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.110.168062","volume":"335","author":"R Herbst","year":"2010","unstructured":"Herbst R, Wang Y, Gallagher S, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335(1):213\u201322.","journal-title":"J Pharmacol Exp Ther."},{"issue":"131","key":"1370_CR17","first-page":"1","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(131):1\u201314.","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"1370_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1352458517740641","volume":"25","author":"MA Agius","year":"2019","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2019;25(2):235\u201345.","journal-title":"Mult Scler."},{"issue":"7","key":"1370_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458515620934","volume":"22","author":"BA Cree","year":"2016","unstructured":"Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica\u2014ethical and design considerations. Mult Scler. 2016;22(7):862\u201372.","journal-title":"Mult Scler."},{"issue":"10206","key":"1370_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet."},{"issue":"Suppl 2","key":"1370_CR21","first-page":"590","volume":"25","author":"J Bennett","year":"2019","unstructured":"Bennett J, Aktas O, Rees W, et al. Characterization of B cell subset changes following treatment of neuromyelitis optica spectrum disorder with inebilizumab: results from the N-MOmentum study randomized control period [abstract no. 1097]. Mult Scler J. 2019;25(Suppl 2):590\u20132.","journal-title":"Mult Scler J."},{"issue":"Suppl 2","key":"1370_CR22","first-page":"896","volume":"25","author":"R Marignier","year":"2019","unstructured":"Marignier R, Bennett JL, Kim HJ, et al. Inebilizumab prevents neuromyelitis optica spectrum disorder disability: outcomes from the N-MOmentum randomised, placebo-controlled, double-masked trial [abstract no. P1604]. Mult Scler J. 2019;25(Suppl 2):896\u20138.","journal-title":"Mult Scler J."},{"issue":"Suppl 2","key":"1370_CR23","first-page":"42","volume":"25","author":"B Cree","year":"2019","unstructured":"Cree B, Bennett J, Kim HJ, et al. The N-MOmentum study\u2014a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results [abstract no. 139]. Mult Scler J. 2019;25(Suppl 2):42\u20134.","journal-title":"Mult Scler J."},{"key":"1370_CR24","doi-asserted-by":"crossref","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. Long-term efficacy and safety of inebilizumab for neuromyelitis optica spectrum disorder in the randomized, double-blind N-MOmentum study and extension [abstract no. 3998]. Neurology. 2020;94(15 Suppl).","DOI":"10.1212\/WNL.94.15_supplement.3998"},{"key":"1370_CR25","unstructured":"Viela Bio. Viela Bio reports first quarter 2020 financial results and program highlights [media release] 13 May 2020. http:\/\/www.vielabio.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01370-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:16:33Z","timestamp":1744701393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01370-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01370-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"29 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. James E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}